<DOC>
	<DOCNO>NCT00069992</DOCNO>
	<brief_summary>Patients ask participate study malignant blood disease Myelodysplastic Syndrome ( MDS ) , Myeloproliferative Disorder ( MPD ) , Acute Myelogenous Leukemia ( AML ) Chronic Myelogenous Leukemia ( CML ) . We feel patient could benefit allogeneic ( mean cell come donor themself ) stem cell transplant . The donor would family member unrelated person felt good match patient . Stem cell cell make bone marrow ( spongy material fill middle bone ) . As stem cell grow , change different type blood cell need . This include red blood cell carry oxygen around body , white blood cell help fight infection , platelet help prevent stop bleeding . Usually , patient give high dos chemotherapy stem cell transplant . High dos chemo destroy bone marrow . Healthy stem cell donor give replace patient 's unhealthy cell . However , complication patient 's disease , high risk life-threatening side effect . These include serious damage organ lung , liver , kidney heart . There also increase risk bacterial , fungal , viral infection . The major problem donor 's stem cell ( also call graft ) find patient 's cell ( host cell ) . The donor cell may try destroy host 's cell . The cell high risk skin , liver intestine . This call graft versus host disease ( GVHD ) fatal . Recently , doctor able use less toxic chemotherapy treatment patient receive transplant . This less toxic treatment help reduce treatment relate problem mention . Patient 's ask involve research study use approach . One major risk low dose treatment patient 's body may reject donor cell . This call graft rejection . This study design see low dose treatment safe effective . This treatment plan add CAMPATH 1H ( special protein call antibody ) low dose chemotherapy regimen . After chemo , patient receive allogeneic ( cell come donor ) stem cell transplant . Adding CAMPATH 1H transplant medicine may help treat disease . CAMPATH 1H may reduce life-threatening treatment related side effect like GVHD . CAMPATH 1H stay active body long time mean may work longer prevent GVHD . CAMPATH 1H destroys lymphocyte , type white cell help fight infection , help prevent graft rejection . We want see addition CAMPATH 1H patient 's pre-transplant low dose chemotherapy decrease side effect allogeneic stem cell transplant , provide curative treatment patient blood disorder .</brief_summary>
	<brief_title>Total-Body Irradiation , Fludarabine , Alemtuzumab Followed By Stem Cell Transplant Treating Patients With Myeloproliferative Disorder , MS , AML , CML</brief_title>
	<detailed_description>We expect patient 's participation study last approximately 18 month 2 year . Before treatment begin , evaluate confirm meet requirement study . The evaluation include HIV testing , HIV ( Human Immunodeficiency Virus ) virus cause Acquired Immune Deficiency Syndrome ( AIDS ) . If patient HIV positive , able treat protocol . The patient need central line . This thin plastic catheter tube place surgery one large vein chest neck . Central line use give medication IV ( intravenous , vein ) take blood sample without endure frequent needle stick . After admission hospital subject receive : Day -6 : single dose total body irradiation Day -5 Day -2 Chemotherapy : Fludarabine plus Campath 1H catheter insert vein ( IV ) Day -2 : FK506 give IV 24 hour period patient take medication mouth . When take oral medication take medication mouth every 12 hour . Day -1 : day rest Day 0 : stem cell transplant ( infusion ) give Day +7 : G-CSF give subcutaneous injection white blood cell ( granulocyte ) great 1000/ul . After transplantation , evaluate follow . Routine history , physical examination , blood test radiology study do need clinical care . Bone marrow aspirate biopsy do day 30 , 60 100 , 180 yearly need .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>INCLUSION CRITERIA : Myelodysplastic syndrome IPSS score &gt; 0 . ( Appendix B ) Or Myeloproliferative disorder Primary Myelofibrosis Lile score 1 2 ( Appendix C ) Polycythemia Vera Essential Thrombocythemia transform AML Myelofibrosis PV `` spend phase '' Acute myelogenous leukemia Chronic myelogenous leukemia Available Healthy Donor without contraindication donation . 5/6 6/6 relate donor 5/6 6/6 unrelated donor ( molecular type DRB1 ) Able give inform consent EXCLUSION CRITERIA : Patient pregnant lactate unwilling use contraceptive . HIV positive patient Uncontrolled intercurrent infection Unstable angina uncompensated congestive heart failure ( Zubrod 3 great ) Severe chronic pulmonary disease require oxygen ( Zubrod 3 great ) Hemodialysis dependent . Active hepatitis cirrhosis total bilirubin , SGOT , SGPT great 3 x normal . Concurrent solid organ malignancy remission , except Stage 0 A prostate cancer . Unstable cerebral vascular disease recent hemorrhagic stroke ( le 6 month ) Active CNS disease hematological disorder .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>polycythemia vera</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>chronic myelogenous leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>